Oxcan
a UK-based medtech company that develops blood tests for early cancer detection using proteomics and AI
Oxcan has raised €16M across 3 funding rounds from 16 investors, most recently a Series A round in Jan 2025. Based in Oxford, UK; active in Healthtech. Data as of 28 Oct 2026.
Oxford, UKwww.oxcan.org ↗
Total raised
€16M
€15,607,734
Funding rounds
3
Investors
16
distinct backers
Active since
2021-09
latest 2025-01
Funding by year
EUR raised per yearOxcan — funding by year — interactive chart.
Data table
| Oxcan — funding by year | |
|---|---|
| 2021 | €1.5M |
| 2023 | €3.5M |
| 2025 | €11M |
Signals
High confidenceRaise-next likelihood66
base rate 44% for Series A
- ▲ In typical raise window
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood10
base rate 11% (2+ rounds)
- ▲ 5y since founding (typical exit age)
- ▼ No recent equity round (debt-only or quiet)
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-01-10 | Series A | €11M | Angel Investors,Aurelium Ventures,Civilization Ventures,Cross Border Impact Ventures,DigitalDx Ventures,Eka Ventures+3 more | View deal → |
| 2023-01-10 | Other | €3.5M | Eka Ventures,LifeArc Ventures,MegaRobo Technologies,Oxford Technology Management | View deal → |
| 2021-09-06 | Seed | €1.5M | Cancer Research UK,Civilisation Ventures,Francis Crick Institute,MegaRobo,Oxford Technology Management | View deal → |